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S U M M A R Y
Parasites threaten human and animal health globally. It is estimated that more than 60% of people on
planet Earth carry at least one parasite, many of them several different species. Unfortunately, parasite
studies suffer from duplications and inconsistencies between different investigator groups. Hence,
groups need to collaborate in an integratedmanner in areas including parasite control, improved therapy
strategies, diagnostic and surveillance tools, and public awareness. Parasite studies will be better served
if there is coordinated management of ﬁeld data and samples across multidisciplinary approach plans,
among academic and non-academic organizations worldwide. In this paper we report the ﬁrst ‘Living
organism-World Molecular Network’, with the cooperation of 167 parasitologists from 88 countries on
all continents. This integrative approach, the ‘Sarcoptes-World Molecular Network’, seeks to harmonize
Sarcoptes epidemiology, diagnosis, treatment, and molecular studies from all over the world, with the
aim of decreasing mite infestations in humans and animals.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Sarcoptes scabiei causes sarcoptic mange in companion,
livestock, and wild animals, as well as scabies in humans. This
parasite has a very broad host range, which includesmore than 100
mammalian species belonging to 27 families from 10 orders.1 In
addition to its potential to cause huge economic loss due to
reduced production and increased mortality in animals,1–3 scabies* Corresponding author. Tel.: +34 669023392; fax: +34 954621125.
E-mail address: samer@ebd.csic.es (S. Alasaad).
1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.01.012is an emerging/re-emerging infectious disease that threatens
human and animal health globally.4–6 There are no accurate
estimates of the prevalence of sarcoptic mange in many of the
different animal populations affected worldwide. However, there
are several examples of how serious an S. scabiei epidemic can be,
causing devastating morbidity.1
It is estimated that 300 million people are infested with scabies
worldwide.7,8 This conservative estimate is most likely too low
considering that the infection is frequently not reported in
humans.9 The prevalence of scabies in African children can be as
high as 40–80%,10,11 and in remote indigenous communities in
northern Australia, up to 50% of children and 25% of adults wereses. Published by Elsevier Ltd. All rights reserved.
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signiﬁcant public health problembecause it is highly prevalent and
complications are frequent.13 Thesemay include, in the presence of
bacterial superinfection, acute post-streptococcal glomerulone-
phritis (PSGN). Children appear to be more commonly affected by
streptococcal superinfection,14 and complications such as PSGN
may be fatal.15 A study performed in The Gambia showed that skin
lesions associated with scabies were the leading portal of entry for
organisms causing septicemia in infants aged 3 months or less.16
The presence and severity of scabies are often associatedwith poor
living conditions and illiteracy.17 Introduction of a single case of
scabies into crowded living conditions can result in an epidem-
ic.18,19 The disease is also a curse in high-income countries where
the prevalence may be increasing due to diagnostic failures,
suspected resistance against some acaricides, and perhaps changes
in social habits.20
Chemotherapy of scabies is important in clinical work. Cheap,
safe, and efﬁcacious drugs are not commonly available in some of
the poorer countries. Emerging drug resistance to S. scabiei has
recently been reported from regions where previously effective
acaricides have been used extensively in socially disadvantaged
communities and in some developing countries.21–23 Researchers
are addressing this in various ways, e.g., by testing (identifying)
novel chemotherapeutics,24–26 by immunological intervention,
and/or by molecular studies of the mite, including, for example,
investigating whether glutathione transferases (GSTs) play any
role in conferring acaricide resistance to S. scabiei and other
mechanisms.27–31
The diagnosis of Sarcoptes is pivotal for assessing eradication
programs32–34 and for epidemiological studies.35 For the experi-
enced dermatologist, the clinical diagnosis of scabies may not
appear difﬁcult, but in fact scabies continues to be a diagnostic
challenge36 because of its diverging clinical manifestations and
many differential diagnoses.24 The deﬁnitive diagnosis of
Sarcoptes infestation can be difﬁcult as in many cases only a
fewmites are present on an infested host, and skinmanifestations
can be subtle or atypical.37 There is a lack of accurate diagnostic
tests for humans.24,38 In addition, for many domestic and wild
animals, including threatened species such as Chamois and
Gorillas,39,40 better speciﬁc Sarcoptes diagnostic methods need to
be developed.
For many years, parasitologists have been immersed in an
ongoing debate as to ‘‘whether or not S. scabiei infecting different
hosts belong to different species or sub-species, or whether they
are, in fact, monospeciﬁc’’.4 Today, the species Sarcoptes scabiei is
divided into varieties based on the host species, e.g., S. scabiei var.
hominis and S. scabiei var. canis. Humans can be infested with
animal varieties, but in this case the disease is usually limited to
certain topographic sites and is self-limited. It has been shown that
an epidemiological relationship does not exist between sarcoptic
mange foci,41 while morphological studies have failed to identify
any signiﬁcant differences between populations of mites.42
Experimental cross-contamination of hosts with some different
S. scabiei varieties is commonly unsuccessful,43 however, cross-
transmission/infection is common in some varieties, e.g., S. scabiei
var. vulpes/canis readily infect dogs and other canids as well as
felids, including domestic European cats.2 In addition, this variety
of S. scabiei also readily infects/infests humans causing pseudo-
scabies.2 Research into ﬁnding an answer to the question of
whether or not S. scabiei is a single species and understanding the
‘host-speciﬁcity’ of the mite has advanced in the last decade with
the advent of polymerase chain reaction (PCR) technology and
molecular marker systems in the genetic era. Molecular studies
based on short fragments of mitochondrial or ribosomal DNA
spacer regions failed to identify S. scabiei populations to the host
species level and geographical localities.42,44–47 Studies on acentral fragment of the 16S gene and the complete cytochrome c
oxidase subunit I gene gene (COI) in combination with microsat-
ellite markers provided some support for a genetic differentiation
of S. scabiei. These genetic markers demonstrated signiﬁcant
relationships between S. scabiei mitochondrial DNA (mtDNA)
haplotypes and microsatellite allele frequencies, and host species
and geographical locations, even at skin-scale level.48–50 Immuno-
logical studies have shown that each variety of S. scabiei tested
produces a range of proteins, both variety-speciﬁc and immuno-
logically identical and shared by the different mite sub-types.51
Clinical manifestations of scabies range from singular nodules
to severe crusted scabies. The underlying causes for these different
manifestations may be found in the immunological host response,
but are not fully understood.
In summary, there is ongoing debate about the host speciﬁcity
and rangeof different Sarcoptes populations onaworldwide scale.
The taxonomical status of this important parasite remains
unclear. Sensitive diagnostic methods are still not available for
many host species, including humans, and new therapeutic
options need to be evaluated. Therefore, well-designed studies
aimed at better understanding the world epidemiology and
transmission dynamics, and the design and development of
sensitive and speciﬁc diagnostic methods are of paramount
importance.
2. Sarcoptes-World Molecular Network initiative
During the last few years we have been working on Sarcoptes
mite epidemiology, diagnosis, treatment, control, clinical aspects,
and genetics, and we are in touchwith colleagues who are working
on Sarcoptes mite epidemiology and control worldwide. This has
enabled us to create the ‘Sarcoptes-World Molecular Network’
(WMN), which currently includes 167 parasitologists from 88
countries from all continents. The Sarcoptes-WMN aims to be a
facilitator of collaborative, mainly molecular research on Sar-
coptes. The network will bring together a wide spectrum of
research communities, aiming to share information, expertise,
samples, and infrastructure. The Sarcoptes-WMN includes differ-
ent institutions such as universities, hospitals, centers of animal
health, medical colleges, public health institutes, private clinics,
medical centers, biological institutes, veterinary research labora-
tories, animal health services, clinical research centers, public
health institutes, and wildlife conservation institutes worldwide.
3. Overall strategy of the Sarcoptes-World Molecular Network
The Sarcoptes-WMNplans to ‘pump-prime’ a newgenetic era of
research into this important parasite, with the aim of achieving the
following:
1. Technology and knowledge transfer among specialists and
human and veterinary practitioners all over the world on the
diagnosis, epidemiology, and management of Sarcoptes scabiei
infestations. This will prevent Sarcoptes research duplication
and foster protocol uniformity, which would fast-track world
research on Sarcoptes.
2. Increase knowledge on the world epidemiology of this ubiqui-
tous parasite.
3. The design and development of universal and speciﬁc Sarcoptes
PCR-based and antibody-based diagnostic methods.
4. Create a global open access ‘Sarcoptes-Specimens World Bank’.
5. Create a global open access ‘Sarcoptes-gDNA World Bank’.
6. Create a global open access database on the world molecular
systematics of the species Sarcoptes, inferred from molecular
marker data from thousands of individual Sarcoptes specimens
worldwide.
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ectoparasite, and establish a possible scenario for Sarcoptes
migration throughout the world.
8. Formulate public and animal health control policies with the
aim of decreasing S. scabiei infections in humans and in
animals.
4. Conclusions
The concept of ‘network’ plays a central role in all branches of
our life. In the area of parasitology research, it is crucial to realize
the importance of standardizing research protocols worldwide.
Availability of biological samples is a recognized limiting factor
for biological and genetic studies; hence the creation of a global
open access ‘Living organism-Specimens/gDNA World Bank’ is of
pivotal interest. Sufﬁciently robust and well-standardized diag-
nostic methods are needed in the form of ready-to-use kits in the
routine laboratory for many host-derived parasite species. The
accurate estimation of parasite host speciﬁcity and rangewill only
be achieved by global epidemiology and molecular studies.
Sarcoptes-WMN is just starting its operations in terms of
technology and knowledge transfer among its members, Sarcoptes
specimen collection, and the design of the epidemiological/
molecular studies. We are aware that such a world genetic
epidemiology study in different host species, countries, and
geographical areas requires wider awareness and collaborations
from all sectors concerned in animal/human welfare, and
especially from those interested in the disease.
To our knowledge this is the ﬁrst world molecular network,
which we hope will serve as a framework around which further
‘Living being-World Molecular Networks’ (Anima-WMN) will be
constructed.
Acknowledgements
We acknowledge the members of the Sarcoptes-World
Molecular Network: Abdulrazak Abyad, Afonso Almeida, Alas-
dair Nisbet, Aleksandar M. Dzamic, Alemayehu Regassa, Alvaro
Oleaga, Aly Raza, Angelica Terashima, Anna Rita Molinar Min,
Antonio Sa´nchez Baca, Apolinario A. Alicante, Arlo Upton, Asoke
K. Basu, Baik Kee Cho, Baswaid Saeed Haj, Ben-Sari Charaf, Bett
Bernard, Brian Lassen, Carl Soulsbury, Christian Gortazar,
Christian Raccurt, Citterio Carlo, Claire Lacroix, Cle´ment Kerah
Hinzoumbe´, Craig G. Burkhart, Dalmiro Cazorla, Diana Zele,
Djohan Vincent, Dominga Soglia, Dumitru Catalin Acatrinei,
Eduardo Gotuzzo, Edward Omudu, Elias Papadopoulos, Elzbieta
Zbikowska, Emmanuel Swai, Emmanuel Serrano, Enala Mwase,
Eva Molin, Evi Jean Bedel, Fabien Hountondji, Farhana Riaz
Chaudhry, Faten Al-Braikan, Francis Gakuya, Galina Efremova,
Golamreza Molavi, Gorazd Vengust, Guangyou Yang, Habibah
Arshad, Hamza Babiker, Han Jianlin, Harold van der Heijden,
Harrat Zoubir, Hayder Ahmed Giha Mohammed, Hetron M
Munang’andu, Hiroyoshi Ninomiya, Ifor Owen, Issiaka Soulama,
Jacqueline Lusat, Janet Wilson, Javier Milla´n Gasca, Jesu´s M.
Pe´rez, Jong-Yil Chai, Jorg Heukelbach, Jorge E. Zavala Castro, Jose´
Enrique Granado, Josephus J. Fourie, Juanita Trejos-Sua´rez,
Kamal Rai, Karla Georges, Kazi Selim Anwar, Khalid Hameed,
Khalid Khallaanyoune, Kosta Y. Mumcuoglu, Krzysztof Solarz,
Kurtis Jai-Chyi Pei, Landry Riba Mandico´, Laza˜r Mircea, Leon
Fourie, Liana de Moura Ariza, Lisette Kohagne Tongue´, Liviu
Miron, Loan Towersey, Michael Lo¨wenstein, Luca Rossi, Luı´s
Miguel Rosalino, Luisa Rambozzi, MalyarFhuk Alexander, Man-
olis Saridomichelakis, Marawan Abu-Madi, Marcela Lareschi,
Marek Asman, Mari Heinonen, Mariana Ahmad, Mario Baldi,
Mark Strong, Mathieu Sarasa, Mavoungou J. Franc¸ois, Mbaye
Mbengue, Mirgani Ali Alhag, Mohamed A. Gebely, Mohamed E.Hamid, Mohamed Gharbi, Mohammad Y. Halami, Natividad
Herna´ndez, Noel Ndeledje Gondje, Olga V. Morozova, Olger
Caldero´n-Arguedas, Omar Hamarsheh, Osman Selc¸uk Aldemir,
Pablo Dı´ez Ban˜os, Paola Sacchi, Patrocinio Morrondo, Piotr
Cuber, Rachael Collins, Rajender Kumar, Ramgopal Laha, Ramo´n
C. Soriguer, Rehana A. Sani, Rhonda Pinckney, Riccardo Orusa,
Richard Maude, Roberto Rasero, Rod Hay, Rodrigo Rosario-Cruz,
Rolf K. Schuster, Sadegh Rahbari, Saeed A. Ba-Angood, Said Amer,
Samar Al Nahhas, Samer Alasaad, Samia Boussaa, Samuel Uade,
Sandra Maione, Sanjay Kumar, Santiago Lavı´n, S.C. Yadav, Scott
Fitzgerald, Sergio Van˜o´ Galva´n, Set Bornstein, Shelley Walton,
Shumaila Naz, Sokolova Tatyana, Soloherilala Raharimanana,
Sorin Pasca, Stefano Sartore, Steffen Rehbein, Steve Harris, Sunil
Kumar Joshi, Syed Afzalul Karim, Tatyana Stetanovska, Thaer
Douri, Thomas Geurden, Toby Leslie, Toku Yanai, Tonay Inceboz,
Ulrich Hengge, Valeria Sabaj, Veronica Spalenza, Wafa Al-
Kandari, Windell L. Rivera, Xing Quan Zhu, Yaxsier de Armas
Rodrı´guez, Yaya Ibrahim Coulibaly, Yee Yee Mya, Yuliya V.
Lopatina, Zuhair Bani Ismail, Werner Zimmermann.
Conﬂict of interest: No conﬂict of interest to declare.
References
1. Bornstein S, Mo¨rner T, Samuel WM. Sarcoptes scabiei and sarcoptic mange. In:
Samuel WM, Pybus MJ, Kocan AA, editors. Parasitic diseases of wild mammals.
Second ed., Ames, Iowa: Iowa State University Press; 2001. p. 107–19.
2. Bornstein S. Sarcoptes scabiei infections of the domestic dog, red fox and pig. PhD
thesis. Uppsala, Sweden: Department of Veterinary Microbiology, Section of
Parasitology, Swedish University of Agricultural Sciences and National Veteri-
nary Institute; 1995.
3. Dagleish MP, Ali Q, Powell RK, Butz D, Woodford MH. Fatal Sarcoptes scabiei
infection of blue sheep (Pseudois nayaur) in Pakistan. J Wildl Dis 2007;43:512–7.
4. Daszak P, Cunningham AA, Hyatt AD. Emerging infectious diseases of wildlife:
global threats to biodiversity and human health. Science 2000;287:443–9.
5. Fthenakis GC, Papadopoulos E, Himonas C, Leontides L, Kritas S, Papatsas J.
Efﬁcacy ofmoxidectin against sarcopticmange and effects onmilk yield of ewes
and growth of lambs. Vet Parasitol 2000;87:207–16.
6. Fthenakis GC, Karagiannidis A, Alexopoulos C, Brozos C, Papadopoulos E. Effects
of sarcoptic mange on the reproductive performance of ewes and transmission
of Sarcoptes scabiei to newborn lambs. Vet Parasitol 2001;95:63–71.
7. Kumaresan J, SathiakumarN. Climate change and its potential impact on health:
a call for integrated action. Bull World Health Organ 2010;88:163.
8. Alexander JO. Arthropods and human skin. Berlin: Springer; 1984.
9. Christophersen J. The epidemiology of scabies in Denmark 1900–1975. Arch
Dermatol 1986;114:747–50.
10. Kristensen JK. Scabies and pyoderma in Lilongwe. Malawi. Prevalence and
seasonal ﬂuctuation. Int J Dermatol 1991;30:699–702.
11. Terry BC, Kanjah F, Sahr F, Kortequee S, Dukulay I, Gbakima AA. Sarcoptes scabiei
infestation among children in a displacement camp in Sierra Leone. Public
Health 2001;115:208–11.
12. Carapetis JR, Connors C, Yarmirr D, Krause V, Currie BJ. Success of a scabies
control program in an Australian aboriginal community. Pediatr Infect Dis J
1997;16:494–9.
13. Heukelbach J, Wilcke T, Winter B, Feldmeier H. Epidemiology and morbidity of
scabies and pediculosis capitis in resource-poor communities in Brazil. Br J
Dermatol 2005;153:150–6.
14. Carapetis JR. The current evidence for the burden of group A streptococcal
diseases. Geneva, Switzerland: World Health Organization; March 2, 2004.
WHO/FCH/CAH/05.07.
15. McCarthy JS, Kemp DJ, Walton SF, Currie BJ. Scabies: more than just an
irritation. Postgrad Med J 2004;80:382–7.
16. Mulholland EK, Ogunlesi OO, Adegbola RA,WeberM, SamBE, Palmer A. Etiology
of serious infections in young Gambian infants. Pediatr Infect Dis J 1999;18:
35–41.
17. Feldmeier H, Jackson A, Ariza L, Lins Calheiros CM, Soares VL, Oliveira FA, et al.
The epidemiology of scabies in an impoverished community in rural Brazil:
presence and severity of disease are associated with poor living conditions and
illiteracy. J Am Acad Dermatol 2009;60:436–43.
18. Andersen BM, Haugen H, Rasch M, Heldal Haugen A, Tageson A. Outbreak of
scabies in Norwegian nursing homes and home care patients: control and
prevention. J Hosp Infect 2000;45:160–4.
19. Obasanjo OO,WuP, ConlonM, Karanﬁl LV, Pryor P,Moler G, et al. An outbreak of
scabies in a teaching hospital: lessons learned. Infect Control Hosp Epidemiol
2001;22:13–8.
20. Lindh J, Persson LM. Allt ﬂer fall av skabb (Increasing cases of scabies).
Smittskydd 2009;4:22–3.
21. Currie BJ, Harumal P, McKinnon M, Walton SF. First documentation of in vivo
and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis 2004;39:
8–12.
S. Alasaad et al. / International Journal of Infectious Diseases 15 (2011) e294–e297 e29722. Bradberry SM, Cage SA, Proudfoot AT, Vale JA. Poisoning due to pyrethroids.
Toxicol Rev 2005;24:93–106.
23. Sanderson H, Laird B, Pope L, Brain R, Wilson C, Johnson D, et al. Assessment of
the environmental fate and effects of ivermectin in aquatic mesocosms. Aquat
Toxicol 2007;85:229–40.
24. Heukelbach J, Feldmeier H. Scabies. Lancet 2006;367:1767–74.
25. Lawrence G, Leafasia J, Sheridan J, Hills S, Wate J, Wate C, et al. Control of
scabies, skin sores and haematuria in children in the Solomon Islands: another
role for ivermectin. Bull World Health Organ 2005;83:34–42.
26. Heukelbach J, Winter B, Wilcke T, Muehlen M, Albrecht S, de Oliveira FA, et al.
Selective mass treatment with ivermectin to control intestinal helminthiases
and parasitic skin diseases in a severely affected population. Bull World Health
Organ 2004;82:563–71.
27. Holt DC, Fischer K, Allen GE,Wilson D,Wilson P, Slade R, et al. Mechanisms for a
novel immune evasion strategy in the scabies mite Sarcoptes scabiei: a multi-
gene family of inactivated serine proteases. J Invest Dermatol 2003;121:
1419–24.
28. Pasay C, Arlian L, Morgan M, Vyszenski-Moher D, Rose A, Holt D, et al. High-
resolution melt analysis for the detection of a mutation associated with
permethrin resistance in a population of scabies mites. Med Vet Entomol
2008;22:82–8.
29. Mounsey KE, Holt DC, McCarthy J, Currie BJ, Walton SF. Scabies: molecular
perspectives and therapeutic implications in the face of emerging drug resis-
tance. Future Microbiol 2008;3:57–66.
30. Molin EU. In vitro characterization of glutathione transferases from Sarcoptes
scabiei. Doctoral thesis No. 2009;80. Uppsala, Sweden: Swedish University of
Agricultural Sciences; 2009.
31. Mounsey KE, Pasay CJ, Arlian L, Morgan MS, Holt DC, Currie BJ, et al. Increased
transcription of glutathione S-transferases in acaricide exposed scabiei mites.
Parasit Vectors 2010;3:43.
32. Jacobson M, Bornstein S, Wallgren P. The efﬁcacy of simpliﬁed eradication
strategies against sarcoptic mangemite infections in swine herdsmonitored by
an ELISA. Vet Parasitol 1997;81:249–58.
33. Jacobson M, Bornstein S, Palmer E, Wallgren P. Elimination of Sarcoptes scabiei
in pig herds by single and double administrations of an avermectin. Acta Vet
Scand 2000;41:227–35.
34. Heinonen M, Bornstein S, Kolhinen R, Saloniemi H, Tuovinen V. Eradication of
porcine sarcoptic mange within a health declared production model. Acta Vet
Scand 2000;41:41–50.
35. Wallgren P, Bornstein S. The spread of porcine sarcoptic mange during the
fattening period revealed by the development of antibodies to Sarcoptes scabiei.
Vet Parasitol 1997;73:315–24.36. Walton SF, Curri BJ. Problems in diagnosing scabies, a global disease in human
and animal populations. Clin Microbiol Rev 2007;20:268–79.
37. Mellanby K. The development of symptoms, parasitic infection and immunity
in human scabies. Parasitology 1944;35:197–206.
38. Haas N, Wagemann B, Hermes B, Henz BM, Heile C, Schein E. Crossreacting IgG
antibodies against fox mite antigens in human scabies. Arch Dermatol Res
2005;296:327–31.
39. Rambozzi L, Menzano A, Lavin S, Rossi L. Biotin–avidin ampliﬁed ELISA for
detection of antibodies to Sarcoptes scabiei in chamois (Rupicapra spp.). Vet Res
2004;35:701–8.
40. Graczyk TK,MudakikwaAB, CranﬁeldMR, Eilenberger U. Hyperkeratoticmange
caused by Sarcoptes scabiei (Acariformes: Sarcoptidae) in juvenile human-habit-
uated mountain gorillas (Gorilla gorilla beringei). Parasitol Res 2001;87:1024–8.
41. Berrilli F, D’Amelio S, Rossi L. Ribosomal and mitochondrial DNA sequence
variation in Sarcoptes mites from different hosts and geographical regions.
Parasitol Res 2002;88:772–7.
42. Fain A. Epidemiological problems of scabies. Int J Dermatol 1978;17:20–30.
43. Arlian LG. Biology, host relations, and epidemiology of Sarcoptes scabiei. Ann Rev
Entomol 1989;34:139–61.
44. Zahler M, Essig A, Gothe R, Rinder H. Molecular analyses suggest monospeci-
ﬁcity of the genus Sarcoptes (Acari: Sarcoptidae). Int J Parasitol 1999;29:759–66.
45. Skerratt LF, Campbell NJ, Murrell A, Walton S, Kemp D, Barker SC. The mito-
chondrial 12S gene is a suitable marker of populations of Sarcoptes scabiei from
wombats, dogs and humans in Australia. Parasitol Res 2002;88:376–9.
46. Gu XB, Yang GY. A study on the genetic relationship of mites in the genus
Sarcoptes (Acari: Sarcoptidae) in China. Int J Acarol 2008;32:183–90.
47. Alasaad S, Soglia D, Spalenza V, Maione S, Soriguer RC, Pe´rez JM, et al. Is ITS-2
rDNA suitable marker for genetic characterization of Sarcoptes mites from
different wild animals in different geographic areas? Vet Parasitol 2009;159:
181–5.
48. Walton SF, Choy JL, Bonson A, Vale A, McBroom J, Taplin D, et al. Genetically
distinct dog-derived and human-derived Sarcoptes scabiei in scabies endemic
communities in northern Australia. Am J Trop Med Hyg 1999;61:542–7.
49. Walton SF, Dougall A, Pizzutto S, Holt D, Taplin D, Arlian LG, et al. Genetic
epidemiology of Sarcoptes scabiei (Acari: Sarcoptidae) in northern Australia. Int J
Parasitol 2004;34:839–49.
50. Alasaad S, Soglia D, Sarasa M, Soriguer RC, Pe´rez JM, Granados JE, et al. Skin-
scale genetic structure of Sarcoptes scabiei populations from individual hosts:
empirical evidence from Iberian ibex-derived mites. Parasitol Res 2008;104:
101–5.
51. Arlian LG, Morgan MS, Arends LL. Immunologic cross-reactivity among various
strains of Sarcoptes scabiei. J Parasitol 1996;82:66–72.
